High Court Won't Review Case Over Skelaxin Antitrust Standing

Law360, New York (October 1, 2012, 4:24 PM EDT) -- The U.S. Supreme Court on Monday refused SigmaPharm Inc.'s bid to revive its lawsuit over royalties for a proposed generic version of prescription muscle relaxant Skelaxin, declining to review a rule that only market competitors and consumers have standing to sue under U.S. antitrust law.

SigmaPharm urged the high court in April to review a Third Circuit decision upholding the dismissal of its antitrust and contract suit that alleges the company was entitled to a share of a settlement between Mutual Pharmaceutical Co. Inc. and King Pharmaceuticals...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.